Edesa Biotech (EDSA) Stock Price, News & Analysis

Company Overview

Edesa Biotech, Inc. is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa’s approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.

Among Edesa’s pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials. In parallel, the company is developing therapeutic vaccine constructs to address oncoviruses and tumor-associated antigens, as well as prophylactic immunizations for broader viral threats. Edesa’s integrated research facilities in Cambridge, Massachusetts support discovery, preclinical evaluation and process development in collaboration with academic and contract manufacturing partners.

Headquartered in Cambridge, Edesa Biotech was founded by a team of immunologists and industry veterans. The company serves global markets through strategic alliances in North America, Europe and Asia. Under the leadership of CEO Steven M. Powell, PhD, Edesa is positioned to advance its pipeline toward late-stage clinical trials and to establish a differentiated platform for both infectious disease prevention and cancer immunotherapy.

Key Stats

• Today's Range: $4.56 to $5.59
• 50-Day Range: $5.14 to $18.27
• 52-Week Range: $0.72 to $20.32
• Volume: 297,400 shs
• Average Volume: 2.72 million shs
• Market Capitalization: $43.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Hold

Edesa Biotech Stock Analysis - MarketRank™

Edesa Biotech scored higher than 40% of companies evaluated by MarketBeat, and ranked 555th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Hold

Consensus Rating

Edesa Biotech has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Edesa Biotech is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Edesa Biotech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Edesa Biotech are expected to grow in the coming year, from ($1.57) to ($1.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Edesa Biotech is -3.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Edesa Biotech is -3.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Edesa Biotech has a P/B Ratio of 10.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.55% of the float of Edesa Biotech has been sold short.

Short Interest Ratio / Days to Cover

Edesa Biotech has a short interest ratio ("days to cover") of 0.57, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Edesa Biotech has recently increased by 9.20%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Edesa Biotech does not currently pay a dividend.

Dividend Growth

Edesa Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 1.03

News Sentiment

Edesa Biotech has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Edesa Biotech this week, compared to 3 articles on an average week.

Search Interest

12 people have searched for EDSA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $6,600.00 in company stock, which represents 0.0150% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Edesa Biotech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,600.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

24.40% of the stock of Edesa Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

5.50% of the stock of Edesa Biotech is held by institutions.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 6/09/2026
• Next Earnings (Estimated): 8/14/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EDSA
• CIK: 1540159
• Web: www.edesabiotech.com
• Phone: (289) 800-9600
• Fax: 805-488-2889
• Employees: 20
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Edesa Biotech: $5.00
• High Price Target: $5.00
• Low Price Target: $5.00
• Potential Upside/Downside: +1.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.19 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -286.52%
• Return on Assets: -75.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.76
• Quick Ratio: 4.76

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.45 per share
• Price / Book: 10.98

Miscellaneous

• Outstanding Shares: 8,890,000
• Free Float: 6,722,000
• Market Cap: $43.92 million
• Optionable: Not Optionable
• Beta: 1.04